{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:10:00Z","timestamp":1778620200442,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018916","name":"Suzhou Municipal Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018916","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.yebeh.2025.110581","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T17:54:04Z","timestamp":1751651644000},"page":"110581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-World safety profile of Fenfluramine in refractory epilepsy: a pharmacovigilance study based on FAERS database"],"prefix":"10.1016","volume":"171","author":[{"given":"Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.yebeh.2025.110581_b0005","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41582-020-0409-4","article-title":"Impact of predictive, preventive and precision medicine strategies in epilepsy","volume":"16","author":"Nabbout","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.yebeh.2025.110581_b0010","first-page":"e203","volume":"10","year":"2025","journal-title":"Public Health"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110581_b0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110581_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107243","article-title":"Premature mortality risk in individuals with convulsive epilepsy: results from a longitudinal, prospective, population-based study","volume":"197","author":"Liu","year":"2023","journal-title":"Epilepsy Res."},{"issue":"9","key":"10.1016\/j.yebeh.2025.110581_b0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","article-title":"New epilepsy therapies in development","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"34","key":"10.1016\/j.yebeh.2025.110581_b0030","doi-asserted-by":"crossref","first-page":"23373","DOI":"10.18632\/oncotarget.25169","article-title":"Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors","volume":"9","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2018","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.yebeh.2025.110581_b0035","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.283.13.1703","article-title":"Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine\/fenfluramine","volume":"283","author":"Gardin","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2025.110581_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100078","article-title":"A review of fenfluramine for the treatment of Dravet syndrome patients","volume":"3","author":"Simon","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110581_b0045","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WCO.0000000000000902","article-title":"Dravet syndrome","volume":"34","author":"Lagae","year":"2021","journal-title":"Curr. Opin. Neurol."},{"issue":"10","key":"10.1016\/j.yebeh.2025.110581_b0050","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-023-01881-w","article-title":"Fenfluramine: a Review in Dravet and Lennox-Gastaut Syndromes","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.yebeh.2025.110581_b0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejpn.2022.05.006","article-title":"Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments","volume":"39","author":"Agarwal","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"8","key":"10.1016\/j.yebeh.2025.110581_b0060","article-title":"A Review of Pharmacology, Clinical Efficacy, and Safety in Epilepsy","volume":"9","author":"Fenfluramine","year":"2022","journal-title":"Children (Basel)"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110581_b0065","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40120-023-00452-1","article-title":"Efficacy and Safety of Fenfluramine in Epilepsy: a Systematic Review and Meta-analysis","volume":"12","author":"Tabaee Damavandi","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.yebeh.2025.110581_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/20420986231154075","article-title":"Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database","volume":"14","author":"Altebainawi","year":"2023","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.yebeh.2025.110581_b0075","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1283247","article-title":"Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yebeh.2025.110581_b0080","first-page":"1","article-title":"Post-marketing safety surveillance of fostamatinib: an observational, pharmacovigilance study leveraging FAERS database","author":"Wei","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.yebeh.2025.110581_b0085","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00002018-200326030-00002","article-title":"Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA)","volume":"26","author":"Brown","year":"2003","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.yebeh.2025.110581_b0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.yebeh.2025.110581_b0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"10.1016\/j.yebeh.2025.110581_b0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.yebeh.2025.110581_b0105","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","article-title":"Borrowing external information to improve Bayesian confidence propagation neural network","volume":"76","author":"Tada","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.yebeh.2025.110581_b0110","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/pds.5624","article-title":"Sensitivity and specificity in signal detection with the reporting odds ratio and the information component","volume":"32","author":"Trillenberg","year":"2023","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.yebeh.2025.110581_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.yebeh.2025.110581_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107866","article-title":"Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know","volume":"226","author":"Odi","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.yebeh.2025.110581_b0125","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/epi.16638","article-title":"Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study","volume":"61","author":"Lai","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110581_b0130","article-title":"Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database","volume":"25(1):206","author":"Liu","year":"2024","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110581_b0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: apharmacovigilance study based ontheFDA adverse Event Reporting System database","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.yebeh.2025.110581_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system","volume":"50","author":"Yan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.yebeh.2025.110581_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.yebeh.2025.110581_b0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.pediatrneurol.2020.01.005","article-title":"Dravet Syndrome: a Review of Current Management","volume":"107","author":"Wheless","year":"2020","journal-title":"Pediatr. Neurol."},{"issue":"6","key":"10.1016\/j.yebeh.2025.110581_b0155","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10571-021-01064-9","article-title":"The Roles of Serotonin in Neuropsychiatric Disorders","volume":"42","author":"Pourhamzeh","year":"2022","journal-title":"Cell. Mol. Neurobiol."},{"issue":"15","key":"10.1016\/j.yebeh.2025.110581_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22157931","article-title":"The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine","volume":"22","author":"Liu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.yebeh.2025.110581_b0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010225","article-title":"Pathological Insight into 5-HT(2B) Receptor Activation in Fibrosing Interstitial Lung Diseases","volume":"22","author":"L\u00f6fdahl","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.yebeh.2025.110581_b0170","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.healun.2021.03.004","article-title":"Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities","volume":"40","author":"Girgis","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"165","key":"10.1016\/j.yebeh.2025.110581_b0175","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0220-2021","article-title":"Recent advances in the management of pulmonary hypertension with interstitial lung disease","volume":"31","author":"Waxman","year":"2022","journal-title":"Eur. Respir. Rev."}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500321X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152550502500321X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:15:30Z","timestamp":1778616930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152550502500321X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":35,"alternative-id":["S152550502500321X"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110581","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World safety profile of Fenfluramine in refractory epilepsy: a pharmacovigilance study based on FAERS database","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110581"}}